Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01747538 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
A Phase 3 study, sponsored by Xoma (US).
- Terminated
- Registry status
- Phase 3
- Development phase
- 281
- Enrollment target
NCT01747538 is a Phase 3 study that was terminated before completion, run by Xoma (US). The registered enrollment target is 281 participants.
The verdict
NCT01747538, a Phase 3 study, was terminated before completion, sponsored by Xoma (US).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 281 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.
Interventions
- DRUG Placebo
- DRUG Dose 2 gevokizumab
- DRUG Dose 1 gevokizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01747538
The ClinicalTrials.gov registry entry for NCT01747538 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01747538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01747538 about?
NCT01747538 is a clinical study titled "Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment". The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.
What is the current status of trial NCT01747538?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 281 participants. The study started on 2012-10.
What interventions are being tested in trial NCT01747538?
The interventions under investigation include: Placebo (DRUG), Dose 2 gevokizumab (DRUG), Dose 1 gevokizumab (DRUG).
Who is sponsoring clinical trial NCT01747538?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.